Here is a list of Health Blogs ordered by Last Commented, posted by members. A Blog is a journal you may enter about your life, thoughts, interesting experiences, or lessons you've learned. Post an opinion, impart words of wisdom, or talk about something interesting in your day. Update your blog on a regular basis, or just whenever you have something to say. Creating a blog is a good way to share something of yourself with others. Reading blogs is a good way to learn more about others. Click here to post a blog.
online today!
quinine, strychnine, any nine...
Trump announces he's taking hydroxychloroquine and days later people are trying to home brew their anti-covid-19 remedies.
Here we go again with folks. News yesterday said Schweppes tonic water with quinine has disappeared off the grocers shelves and they are predicting a rise in poisonings with 'monkey see monkey do' folks trying any similar defense to the COVID-19 pandemic.
...and you though no one would be so gullible to try bleach injections, this one could be exponential!
Here we go again with folks. News yesterday said Schweppes tonic water with quinine has disappeared off the grocers shelves and they are predicting a rise in poisonings with 'monkey see monkey do' folks trying any similar defense to the COVID-19 pandemic.
...and you though no one would be so gullible to try bleach injections, this one could be exponential!
Trump Takes ‘Historic’ Action To Move Pharmaceutical Manufacturing Out Of China, Back To U.S.
Seeking to secure the nation's supply of critical medications, the Trump administration has signed a $354 million contract that would create the nation's first strategic stockpile of key ingredients needed to make medicines.
The agreement was signed Monday with Phlow Corp., a generic drug maker based in Virginia. According to a news release to be made public Tuesday, the project will use federal funds from the Biomedical Advanced Research and Development Authority under the Department of Health and Human Services.
The goal is twofold: to enable the U.S. to manufacture essential drugs at risk of shortage and to create a reserve of active pharmaceutical ingredients to reduce the dependence on foreign suppliers.
Phlow's CEO, Dr. Eric Edwards, told NBC News that the company had been in discussions with the administration back in November but that the project was fast-tracked once COVID-19 hit.
"We said: 'We have a short-term and long-term solution. We know that there are certain key essential generic medicines that are going to go into shortage if this thing starts spreading,'" Edwards said. "There were drugs that were already on the FDA drug shortage list long before COVID-19 and we already saw what was happening with PPE, and we knew this was going to be as bad or even worse."
"PPE" is short for personal protective equipment used by medical personnel.
Edwards said the company is set to provide more than a dozen medications and ingredients used for sedation, pain management, blood pressure control and antibiotics. It has already produced over 1.6 million doses of five essential generic drugs used to treat COVID-19 that were added to the U.S. Strategic National Stockpile in March.
Phlow will be manufacturing the drugs in partnership with the nonprofit pharmaceutical company Civica Rx, Virginia Commonwealth University and AMPAC Fine Chemicals, a manufacturer of active pharmaceutical ingredients. The total value of the Phlow contract is up to $812 million, which includes the possibility of an additional $458 million to keep the project going long term. It was first reported by The New York Times.
"This is an historic turning point in the battle of President Trump to bring our pharmaceutical manufacturing and supply chain home to American soil," White House trade adviser Peter Navarro told NBC News.
The move would help address a longstanding concern in the health care sector, experts said, as the vast majority of raw drug ingredients are produced overseas, mainly in India and China because of cheap manufacturing costs and less stringent regulations. Experts have long feared a significant supply disruption caused by the country's dependence on foreign manufacturing.
The coronavirus pandemic has forced hospitals to scramble to source critical medications for COVID-19 patients. In some cases, fear of shortages has created a competitive landscape among health care providers seeking the same medications.
Arash Dabestani, senior director of pharmacy at NYU Langone Health in New York, said getting the necessary drugs often involves a team of six people making calls to wholesalers, distributors and direct manufacturers as early as 9 a.m. And even then, they may get only half the supply they really need.
"It's like an auction," Dabestani said. "Whoever screams the loudest gets it."
Read more:
The agreement was signed Monday with Phlow Corp., a generic drug maker based in Virginia. According to a news release to be made public Tuesday, the project will use federal funds from the Biomedical Advanced Research and Development Authority under the Department of Health and Human Services.
The goal is twofold: to enable the U.S. to manufacture essential drugs at risk of shortage and to create a reserve of active pharmaceutical ingredients to reduce the dependence on foreign suppliers.
Phlow's CEO, Dr. Eric Edwards, told NBC News that the company had been in discussions with the administration back in November but that the project was fast-tracked once COVID-19 hit.
"We said: 'We have a short-term and long-term solution. We know that there are certain key essential generic medicines that are going to go into shortage if this thing starts spreading,'" Edwards said. "There were drugs that were already on the FDA drug shortage list long before COVID-19 and we already saw what was happening with PPE, and we knew this was going to be as bad or even worse."
"PPE" is short for personal protective equipment used by medical personnel.
Edwards said the company is set to provide more than a dozen medications and ingredients used for sedation, pain management, blood pressure control and antibiotics. It has already produced over 1.6 million doses of five essential generic drugs used to treat COVID-19 that were added to the U.S. Strategic National Stockpile in March.
Phlow will be manufacturing the drugs in partnership with the nonprofit pharmaceutical company Civica Rx, Virginia Commonwealth University and AMPAC Fine Chemicals, a manufacturer of active pharmaceutical ingredients. The total value of the Phlow contract is up to $812 million, which includes the possibility of an additional $458 million to keep the project going long term. It was first reported by The New York Times.
"This is an historic turning point in the battle of President Trump to bring our pharmaceutical manufacturing and supply chain home to American soil," White House trade adviser Peter Navarro told NBC News.
The move would help address a longstanding concern in the health care sector, experts said, as the vast majority of raw drug ingredients are produced overseas, mainly in India and China because of cheap manufacturing costs and less stringent regulations. Experts have long feared a significant supply disruption caused by the country's dependence on foreign manufacturing.
The coronavirus pandemic has forced hospitals to scramble to source critical medications for COVID-19 patients. In some cases, fear of shortages has created a competitive landscape among health care providers seeking the same medications.
Arash Dabestani, senior director of pharmacy at NYU Langone Health in New York, said getting the necessary drugs often involves a team of six people making calls to wholesalers, distributors and direct manufacturers as early as 9 a.m. And even then, they may get only half the supply they really need.
"It's like an auction," Dabestani said. "Whoever screams the loudest gets it."
Read more:
HR 6666
Why would Congress name a bill that in the first place? Why not HR 5555? 
Anyway, I just recently heard about this and very briefly read about it and don't know much about the specfics the bill talks about. I am just interested in knowing why they would name it that? A bill....that makes it, from my understanding, mandatory for us to receive a vaccine.
anyway....
Anyway, I just recently heard about this and very briefly read about it and don't know much about the specfics the bill talks about. I am just interested in knowing why they would name it that? A bill....that makes it, from my understanding, mandatory for us to receive a vaccine.
anyway....
As a public service
This SHOULD go without saying, BUT.....
Lets just say, that in no large group is everyone going to be
of the same intelligence. That will not happen.
We are unique individuals.
Having read some of the things I see on here,
believe it or not, I truly worry about some of you especially after witnessing
how some of you are easily mislead.
Thus, just in case the hydroxychloroquin mishaps were not enough,
please do not inject disinfectant, no matter what the idiot-in-chief says.
And in case there are any doubts, here is the words of the FDA commissioner on this topic;
From CNN;
Lets just say, that in no large group is everyone going to be
of the same intelligence. That will not happen.
We are unique individuals.
Having read some of the things I see on here,
believe it or not, I truly worry about some of you especially after witnessing
how some of you are easily mislead.
Thus, just in case the hydroxychloroquin mishaps were not enough,
please do not inject disinfectant, no matter what the idiot-in-chief says.
And in case there are any doubts, here is the words of the FDA commissioner on this topic;
From CNN;
In response to:
Don't eat or inject yourself with disinfectant, warns FDA commissioner
On Thursday, US President Donald Trump suggested that scientists may want to explore bringing UV light inside the body to kill a Covid-19 infection, or should consider the use of disinfectant that "knocks it out in a minute ... by injection inside or almost a cleaning."
"I certainly wouldn't recommend the internal ingestion of a disinfectant," said US Food and Drug Administration commissioner Dr. Stephen Hahn, who is also a member of the White House coronavirus task force.
Dr. Leana Wen, the former Baltimore health commissioner, agreed that nobody should be ingesting bleach or other disinfectants.
"I don't think there's any need to hedge on that," she said. "Do not try these things at home, and follow your doctor's advice and follow good public health guidance."
Don't eat or inject yourself with disinfectant, warns FDA commissioner
On Thursday, US President Donald Trump suggested that scientists may want to explore bringing UV light inside the body to kill a Covid-19 infection, or should consider the use of disinfectant that "knocks it out in a minute ... by injection inside or almost a cleaning."
"I certainly wouldn't recommend the internal ingestion of a disinfectant," said US Food and Drug Administration commissioner Dr. Stephen Hahn, who is also a member of the White House coronavirus task force.
Dr. Leana Wen, the former Baltimore health commissioner, agreed that nobody should be ingesting bleach or other disinfectants.
"I don't think there's any need to hedge on that," she said. "Do not try these things at home, and follow your doctor's advice and follow good public health guidance."
What is your SpO2 and bpm?
SpO2 average @ 97
PR bpm 72
an oximeter can be a valuable tool in the house,
PR bpm 72
an oximeter can be a valuable tool in the house,
online today!
1600 Covid Avenue, Washington, D.C.
It's been a busy month in the White House where Trump's valet, 2 Pence employees, 3 white house staff members and something like 11 secret service agents have all tested positive for the coronavirus.
Testing, testing, testing and serious concern for top officials in the oval office.
I shouldn't speculate on this one...
Testing, testing, testing and serious concern for top officials in the oval office.
I shouldn't speculate on this one...
online today!
Unmasked...
They reopened a popular South Florida beach and 7,000 people showed up not wearing masks with a total defiance of social distancing. So the city was forced to close the beach again. C'mon people... use your brains.
Restaurants are soon to reopen allowed with only 25% capacity. It's reported some will annex their parking lots setting up tables distanced so they can service customers and maintain compliance. They have a plan!
Local news reports say many retail stores have masks for sale.
It's good to hear this.
While I find the image below to be funny, if the outside of the mask is contaminated and your hands touch the straw and cap, there is a strong chance the virus will pass into the mask.
Restaurants are soon to reopen allowed with only 25% capacity. It's reported some will annex their parking lots setting up tables distanced so they can service customers and maintain compliance. They have a plan!
Local news reports say many retail stores have masks for sale.
It's good to hear this.
While I find the image below to be funny, if the outside of the mask is contaminated and your hands touch the straw and cap, there is a strong chance the virus will pass into the mask.
Excellent update on the Covid-19 vaccine front
Today in Bloomberg;
(continued in my first comment below)
In response to:
Virus Vaccine May Be Ready for Mass Production By Autumn, Oxford Professor Says
By Jason Gale
and Stephanie Baker
April 17, 2020, 2:23 AM EDT Updated on April 17, 2020, 7:25 AM EDT
A coronavirus vaccine trial by University of Oxford researchers aims to get efficacy results by September, and manufacturing is already underway.
A team led by Sarah Gilbert, a professor of vaccinology, has recruited 500 volunteers from the ages of 18 to 55 for the early- and mid-stage randomized controlled trial. It will be extended to older adults and then to a final stage trial of 5,000 people. Gilbert said that the timing is ambitious but achievable.
“We would hope to have at least some doses that are ready to be used by September,” she said in an interview. “There won’t be enough for everywhere by then, but the more manufacturing we can do starting from now, then the more doses there will be.”
Volunteers to take part in the trial have been abundant, she said, and it’s no longer accepting new subjects.
Gilbert, whose research on vaccines began at the University of Oxford in 1994, was awarded a 2.2 million pound ($2.8 million) grant from the U.K.’s National Institute for Health Research and U.K. Research and Innovation in March to scale up her team’s efforts to move into Covid-19 vaccine research.
The group’s experimental immunization is among the first to enter clinical trials. The World Health Organization counts 70 vaccine candidates in development, with three others in human testing. They are from CanSino Biological Inc. and the Beijing Institute of Biotechnology; Inovio Pharmaceuticals Inc.; and Moderna Inc. along with the National Institute of Allergy and Infectious Diseases.
Gilbert’s trial divides 510 participants into five groups that will be observed for about six months with the option for a follow-up visit about a year after entering the trial. One group will receive a second intramuscular shot of the vaccine four weeks after the initial immunization.
The research aims to determine the efficacy, safety and immunogenicity of the candidate vaccine, named ChAdOx1 nCoV-19. A vaccine against meningococcal disease will be given to participants who will be randomly chosen for control purposes.
Overseas Partners?
ChAdOx1 nCoV-19 is a so-called recombinant viral vector vaccine. It’s made from a harmless virus that’s been altered to produce the surface spike protein of the pandemic-causing SARS-CoV-2 virus.
The vaccine acts by priming the immune system to recognize and attack the coronavirus, stimulating a T-cell response. It uses the same technology as a shot Gilbert’s team previously developed for the related MERS coronavirus. That vaccine appeared to be safe in animal and early-stage human testing, giving confidence for the coronavirus version.
“We’re doing safety testing,” Gilbert said, “but we’re not concerned.”
Gilbert’s team has used the same technology for about 10 different vaccines, she said. The challenge that now arises is testing the vaccine even as virus infection rates vary.
“It’s going to be complicated trying to determine vaccine efficacy when the virus transmission in different places is going up and then going down again,” she said. “The trial has to be set up in the right place at the right time and that’s very hard to predict. That’s why we’re planning to do multiple trials in multiple countries.”
Another hurdle is money.
“We have some funding but we don’t have all of it yet,” she said. “You can’t just go and start manufacturing at large scale. You have to put a lot of things in place and that’s what we’re trying to do at the moment. It’s in the order of tens of millions of pounds.”
The WHO is creating a forum for everyone developing Covid-19 vaccines to share their plans and initial findings, according to Gilbert.
Virus Vaccine May Be Ready for Mass Production By Autumn, Oxford Professor Says
By Jason Gale
and Stephanie Baker
April 17, 2020, 2:23 AM EDT Updated on April 17, 2020, 7:25 AM EDT
A coronavirus vaccine trial by University of Oxford researchers aims to get efficacy results by September, and manufacturing is already underway.
A team led by Sarah Gilbert, a professor of vaccinology, has recruited 500 volunteers from the ages of 18 to 55 for the early- and mid-stage randomized controlled trial. It will be extended to older adults and then to a final stage trial of 5,000 people. Gilbert said that the timing is ambitious but achievable.
“We would hope to have at least some doses that are ready to be used by September,” she said in an interview. “There won’t be enough for everywhere by then, but the more manufacturing we can do starting from now, then the more doses there will be.”
Volunteers to take part in the trial have been abundant, she said, and it’s no longer accepting new subjects.
Gilbert, whose research on vaccines began at the University of Oxford in 1994, was awarded a 2.2 million pound ($2.8 million) grant from the U.K.’s National Institute for Health Research and U.K. Research and Innovation in March to scale up her team’s efforts to move into Covid-19 vaccine research.
The group’s experimental immunization is among the first to enter clinical trials. The World Health Organization counts 70 vaccine candidates in development, with three others in human testing. They are from CanSino Biological Inc. and the Beijing Institute of Biotechnology; Inovio Pharmaceuticals Inc.; and Moderna Inc. along with the National Institute of Allergy and Infectious Diseases.
Gilbert’s trial divides 510 participants into five groups that will be observed for about six months with the option for a follow-up visit about a year after entering the trial. One group will receive a second intramuscular shot of the vaccine four weeks after the initial immunization.
The research aims to determine the efficacy, safety and immunogenicity of the candidate vaccine, named ChAdOx1 nCoV-19. A vaccine against meningococcal disease will be given to participants who will be randomly chosen for control purposes.
Overseas Partners?
ChAdOx1 nCoV-19 is a so-called recombinant viral vector vaccine. It’s made from a harmless virus that’s been altered to produce the surface spike protein of the pandemic-causing SARS-CoV-2 virus.
The vaccine acts by priming the immune system to recognize and attack the coronavirus, stimulating a T-cell response. It uses the same technology as a shot Gilbert’s team previously developed for the related MERS coronavirus. That vaccine appeared to be safe in animal and early-stage human testing, giving confidence for the coronavirus version.
“We’re doing safety testing,” Gilbert said, “but we’re not concerned.”
Gilbert’s team has used the same technology for about 10 different vaccines, she said. The challenge that now arises is testing the vaccine even as virus infection rates vary.
“It’s going to be complicated trying to determine vaccine efficacy when the virus transmission in different places is going up and then going down again,” she said. “The trial has to be set up in the right place at the right time and that’s very hard to predict. That’s why we’re planning to do multiple trials in multiple countries.”
Another hurdle is money.
“We have some funding but we don’t have all of it yet,” she said. “You can’t just go and start manufacturing at large scale. You have to put a lot of things in place and that’s what we’re trying to do at the moment. It’s in the order of tens of millions of pounds.”
The WHO is creating a forum for everyone developing Covid-19 vaccines to share their plans and initial findings, according to Gilbert.
(continued in my first comment below)
Evidence that Covid 19 was around in November?
A good friend of mine works at a hospital lab in a big city. Well, she does not play any direct role in the scenario, but she might have prompted indirectly some of the action to be taken.
Anyway, she has just informed....
Her mom's boyfriend was very sick in November. His doctor thought he might have lung cancer, but it was later diagnosed as pneumonia.
Just recently, in fact the results were gotten today. He and his doctor decided to test him for the anti-bodies of Covid 19, and his test came back positive.....meaning he has had Covid 19.
Well...either he had the disease in November, or he caught the virus later on and never even knew he had it because there were no signs he had it.
I am not doctor, but if I was a betting man (and I am) I would put my money on the fact he had the virus back in November.
Anyway, she has just informed....
Her mom's boyfriend was very sick in November. His doctor thought he might have lung cancer, but it was later diagnosed as pneumonia.
Just recently, in fact the results were gotten today. He and his doctor decided to test him for the anti-bodies of Covid 19, and his test came back positive.....meaning he has had Covid 19.
Well...either he had the disease in November, or he caught the virus later on and never even knew he had it because there were no signs he had it.
I am not doctor, but if I was a betting man (and I am) I would put my money on the fact he had the virus back in November.
Work Restricted
I see a blog regarding working from
The home place as opposed to pre
Covid.
My own thoughts would be if you can
You should. It is going to be a long road
Back for our Economy, as well as for
Others.
I am not working, the hotel that has my
Employment is closed indefinitely but
My job is safe. My hours probably will
Be less. I will be okay.
In lreland the restrictions are starting
To be eased. Hopefully, not too soon.
There is pressure on governments
Now as people are struggling and
Also the fine weather which is a bigger
Test now.
The home place as opposed to pre
Covid.
My own thoughts would be if you can
You should. It is going to be a long road
Back for our Economy, as well as for
Others.
I am not working, the hotel that has my
Employment is closed indefinitely but
My job is safe. My hours probably will
Be less. I will be okay.
In lreland the restrictions are starting
To be eased. Hopefully, not too soon.
There is pressure on governments
Now as people are struggling and
Also the fine weather which is a bigger
Test now.
A Blog is a journal you may enter about your life, your thoughts, interesting experiences, or lessons you have learned. It's your own page on Connecting Singles that you can update on a regular basis, or just whenever you have something to say. You can write about an opinion, impart words of wisdom, or talk about something interesting in your day. Creating a blog is a good way to share something of yourself with Connecting Singles members. Reading blogs is a good way to learn more about members you have met here. Please be sure to read the blog rules before posting.
Would YOU like to post a blog on Connecting Singles? Have you written blogs that you'd like to share with other members? Posting your blogs shows your skill and creativity and helps members get to know you better. Your blog will appear on the Connecting Singles Blogs page and also in a link on your profile page. Click here to post a blog »